Regulating the immune response to tumours

Betts, Gareth James, Clarke, Sarah Louise, Richards, Hannah E., Godkin, Andrew James ORCID: https://orcid.org/0000-0002-1910-7567 and Gallimore, Awen Myfanwy ORCID: https://orcid.org/0000-0001-6675-7004 2006. Regulating the immune response to tumours. Advanced Drug Delivery Reviews 58 (8) , pp. 948-961. 10.1016/j.addr.2006.05.006

Full text not available from this repository.

Abstract

Naturally occurring regulatory T cells (Tregs) have been shown to suppress immune responses to self-antigens, thereby limiting autoimmunity. In the case of tumours, where immune responses to self-antigens are beneficial and lead to elimination of the tumour, such suppressive activity is actually detrimental to the host. Manipulation of Tregs holds great promise for the immunotherapy of cancer. Several studies performed using rodent models and indicate that Tregs cells inhibit effective anti-tumour immune responses and that their removal promotes tumour rejection. The increasing number of studies of Tregs in patients with cancer also point to a role for these cells in promoting disease progression. This review summarises the findings of these studies and addresses the advantages and potential pitfalls of manipulating Treg activity for the treatment of cancer.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	Tumour immunity; T regulatory cells.
Publisher:	Elsevier
ISSN:	0169-409X
Last Modified:	27 Oct 2022 10:06
URI:	https://orca.cardiff.ac.uk/id/eprint/68921

Citation Data

Cited 52 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item